Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

[1]  Scott E. Smith,et al.  A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome , 2012, Cancer.

[2]  J. Mesirov,et al.  Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199) , 2011 .

[3]  F. Ali-Osman,et al.  Abstract B229: Novel ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity. , 2011 .

[4]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[5]  E. Laborde.  Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death , 2010, Cell Death and Differentiation.

[6]  A. Raza,et al.  Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure , 2010, Journal of hematology & oncology.

[7]  Scott E. Smith,et al.  Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. , 2009, Blood.

[8]  Paolo Bernasconi,et al.  Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a review , 2008, British journal of haematology.

[9]  J. Keck,et al.  Induction of apoptosis by TLK199 in human leukemia cells , 2008 .

[10]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[11]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[12]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q , 2007 .

[13]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[14]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[15]  C. Bloomfield,et al.  Cytogenetics in Acute Leukemia , 2022 .

[16]  D. Steensma,et al.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. , 2003, Leukemia research.

[17]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[18]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.